Literature DB >> 1699593

IL-1 and IL-4 as reciprocal regulators of IL-2 induced lymphocyte cytotoxicity.

N Ebina1, D Gallardo, H Shau, S H Golub.   

Abstract

Interleukin 4 (IL-4) suppresses the interleukin 2 (IL-2) induced lymphokine-activated killer (LAK) cell development from human peripheral blood mononuclear cells (PBMC). Suppression is observed at high (1,000 U ml-1) as well as low (10 U ml-1) concentrations of IL-2. IL-4 needs to be present at the beginning of the IL-2 culture to exert the suppressive effect. IL-4 also inhibits the development of CD25 (Tac) antigen on the PBMC cultured in IL-2. Interleukin 1 (IL-1) can reverse the suppressive effect of IL-4 on LAK induction when added at the early phase of the IL-2 culture. IL-1 enhances IL-2 induced LAK development, which may partially explain the reversion of IL-4 inhibition by IL-1. IL-1 also reverses the inhibitory effect of IL-4 on the development of CD25 antigen expression, although IL-1 alone does not enhance the induction of CD25 expression in PBMC cultured by IL-2. Furthermore, IL-4 suppresses IL-2 induced IL-1 production in PBMC. Thus, suppression of CD25 may be a pathway for the suppression of LAK induction. The expression of CD56 is not directly associated with the expression of LAK activity. IL-4, IL-1 or combination of the two cytokines has no effect on IL-2 induced expression of CD56. These results indicate that IL-4 has an antagonistic effect and IL-1 has a synergistic effect on IL-2-induced LAK development.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699593      PMCID: PMC1971504          DOI: 10.1038/bjc.1990.341

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

Review 1.  Signals for activation of natural killer and natural killer-like activity.

Authors:  H Y Shau; S H Golub
Journal:  Nat Immun Cell Growth Regul       Date:  1985

2.  IL-4 (B cell-stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity.

Authors:  D W Horohov; J A Crim; P L Smith; J P Siegel
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

3.  Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells.

Authors:  W L Crump; L B Owen-Schaub; E A Grimm
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

4.  IL-4 down-regulates IL-1 and TNF gene expression in human monocytes.

Authors:  R Essner; K Rhoades; W H McBride; D L Morton; J S Economou
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

5.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities.

Authors:  J P Siegel; M Sharon; P L Smith; W J Leonard
Journal:  Science       Date:  1987-10-02       Impact factor: 47.728

6.  The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.

Authors:  M Tsudo; C K Goldman; K F Bongiovanni; W C Chan; E F Winton; M Yagita; E A Grimm; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

8.  IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.

Authors:  H Spits; H Yssel; X Paliard; R Kastelein; C Figdor; J E de Vries
Journal:  J Immunol       Date:  1988-07-01       Impact factor: 5.422

9.  Il-4 is an endogenous T cell growth factor during the immune response to a syngeneic retrovirus-induced tumor.

Authors:  D E Kern; D J Peace; J P Klarnet; M A Cheever; P D Greenberg
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

10.  Activation of natural killer cells via the p75 interleukin 2 receptor.

Authors:  J H Phillips; T Takeshita; K Sugamura; L L Lanier
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

View more
  7 in total

1.  CD4+ T-helper-cell responses in mice with low-level Candida albicans infection.

Authors:  A Mencacci; R Spaccapelo; G Del Sero; K H Enssle; A Cassone; F Bistoni; L Romani
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

2.  Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes.

Authors:  B Brooks; H Parry; J Lawry; R Rees
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

3.  High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma.

Authors:  E Roussel; M C Gingras; E A Grimm; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

Review 4.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

5.  Local expression of antiinflammatory cytokines in cancer.

Authors:  M Yamamura; R L Modlin; J D Ohmen; R L Moy
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

6.  Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.

Authors:  I Vollenweider; R Moser; P Groscurth
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

7.  Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma.

Authors:  Elisabeth Oelmann; Harald Stein; Wolfgang E Berdel; Hermann Herbst
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.